Back to top
more

PROCEPT BIOROBO (PRCT)

(Real Time Quote from BATS)

$21.20 USD

21.20
74,674

-0.05 (-0.24%)

Updated Aug 25, 2026 10:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (149 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Indrajit Bandyopadhyay headshot

ISRG Trading 4% Below All-Time High: Should You Buy the Stock Now?

by Indrajit Bandyopadhyay

ISRG trades just 4% below its record high after a 32% surge over the past three months, driven by strong procedure growth, rising utilization, and early traction for the da Vinci 5 system.

Zacks Equity Research

PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Beats Revenue Estimates

by Zacks Equity Research

PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of +7.32% and +3.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mettler-Toledo (MTD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Mettler-Toledo (MTD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: PROCEPT BioRobotics Corporation (PRCT) Q3 Earnings Expected to Decline

by Zacks Equity Research

PROCEPT BioRobotics (PRCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Stereotaxis Rolls Out Synchrony System in EU and Files for FDA Approval

by Zacks Equity Research

STXS expands its digital surgery vision with the EU launch of its Synchrony System and an FDA submission for market entry.

Indrajit Bandyopadhyay headshot

ISRG Stock Down More than 13% in 3 Months: How to Play the Stock?

by Indrajit Bandyopadhyay

Intuitive Surgical shares are down 13% in three months as margin pressures weigh on the stock, but strong procedure growth keeps its long-term story intact.

Indrajit Bandyopadhyay headshot

SP Platform's 88% Procedure Growth: The Next Frontier for ISRG?

by Indrajit Bandyopadhyay

Intuitive Surgical's SP platform posts 88% procedure growth in Q2, driven by a 112% surge in Korea and expanding adoption in colorectal and thoracic surgery.

Zacks Equity Research

PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of +14.63% and -0.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of +100.00% and +7.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Si-Bone (SIBN) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Si-Bone (SIBN) delivered earnings and revenue surprises of +26.32% and +0.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?